Amarantus BioScience, Inc. (AMBS) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Amarantus BioScience is focused on developing certain biologics surrounding the intellectual property and proprietary technologies the company owns to treat and/or diagnose Parkinson’s disease, traumatic brain injury, ischemic heart disease, and other human diseases. Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. For more information visit the company’s Web site at www.amarantus.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
